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One of the most widely recognized achievements developed at The Hutch is bone marrow 
transplantation to treat cancer patients. Among the myriad issues surrounding such a complex 
procedure is the increased risk of infection or reactivation of cytomegalovirus (CMV) and 
development of CMV disease following transplantation. Current treatment strategies for CMV have 
severe side effects and drug resistance can develop. A recent study reported in the New England 
Journal of Medicine by senior author Dr. Michael Boeckh of the Vaccine and Infectious Disease 
Division and colleagues shows promising results for a new antiviral drug to treat and/or prevent CMV 
infection following transplantation. 
Patients who undergo allogeneic hematopoietic cell transplantation, often do so as a last chance 
attempt to cure them of leukemia or lymphoma. During the procedure, the patient's immune system 
is severely weakened by chemotherapy and/or radiation before stem cells are transplanted from a 
healthy donor. Due to a depleted immune system and the introduction of new immune system cells 
that are genetically distinct from the recipient's cells, the patient is highly susceptible to many 
infections, as well as graft versus host disease. Infection with CMV affects this population of patients 
with particularly high prevalence. 
Although between 50% and 80% of adults in the U.S. are infected with CMV, the virus forms a 
lifelong latent infection with little or no symptoms in people with a healthy immune system. However, 
in immunocompromised individuals, such as hematopoietic cell transplant patients, CMV infection 
can cause pneumonia, retinitis, gastrointestinal disease and an increased chance of death. These 
outcomes arise despite the administration of available antiviral agents. Furthermore, the use of 
current drugs is limited because of adverse effects such as toxicity to blood cells, the very cells that 
the transplantation was carried out to replace. 
A new antiviral drug CMX001 "was originally developed as an oral treatment for smallpox, but other 
studies have suggested it is effective in treating a range of other viruses," explains Dr. Boeckh. "For 
that reason, CMX001 has been stirring considerable interest among researchers and clinicians 
alike." Following promising preclinical results and several initial clinical trials, the drug was tested in 
a large multi-center cohort of allogeneic hematopoietic cell transplant recipients in a phase II trial. 
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The study involved 230 allogeneic hematopoietic cell transplant patients recruited at 27 centers. 
Patients either received the new antiviral drug CMX001 at varying doses, or a placebo. The duration 
of the treatment was from 9 to 11 weeks. Following the treatment period, CMV DNA was detected in 
plasma by polymerase chain reaction to monitor for CMV events, defined as CMV disease or CMV 
DNA greater than 200 copies per milliliter. The investigators found that only 10% of patients 
receiving 100 mg of CMX001 twice weekly experienced a CMV event, compared to 37% in the 
placebo group (p = 0.002). The most common side effect of the treatment was diarrhea, which was 
most common and often serious in the patients receiving the highest dose of CMX001 (200 mg twice 
weekly). However, for patients receiving 100 mg twice weekly instances of diarrhea were milder in 
nature and did not result in an increased rate of withdrawals from the study. 
"The results of this study are very encouraging for the field of hematopoietic cell transplantation, as 
CMX001 could prevent or treat a large number of potentially fatal viral infections for which we don’t 
currently have good treatment," adds Dr. Boeckh. The drug is also being tested for efficacy against 
other life-threatening viral infections including adenovirus, herpes simplex virus and monkeypox 
virus. The promising results shown by CMX001 bode well for this new antiviral. "This drug could 
potentially be a game-changer," predicts Dr. Boeckh. "The phase III study to definitively prove the 
efficacy of CMX001 is now ongoing." 
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Image provide by Dr. Michael Boeckh, adapted from the original 
article. 
Time to CMV disease or CMV plasma DNA > 1000 copies/mL 
according to CMX001 study groups. Twice weekly treatment of 
100 mg or 200 mg CMX001 showed the strongest ability to 
prevent CMV disease. 
 
